Chinese biopharmaceutical company: LM-2417 completes the enrollment of the first patient in Phase I clinical trial in China.

Chinese biopharmaceutical company announced that the innovative drug LM-2417 "NaPi2b/4-1BB Bispecific Antibody" of its subsidiary Sinobioway Pharmceutical Group has enrolled the first patient in Phase I clinical trial in China. Preclinical data indicate that LM-2417 not only induces lasting anti-tumor immune memory, but also shows significant synergistic effects when used in combination with other immunotherapy drugs. These characteristics make LM-2417 have the potential to become a pioneer in similar immunotherapy. This clinical trial is an open-label, dose-escalation, and dose-expansion Phase I/II clinical study of injection of LM-2417 as monotherapy or in combination with other anti-tumor drugs in patients with advanced malignant solid tumors to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy.